Evidence map›Paper›PMID 39192979›Full record

ReviewFrontiers in immunology2024

The role of metabolic reprogramming in immune escape of triple-negative breast cancer.

Ruochen Bao, Hongtao Qu, Baifeng Li, Kai Cheng, Yandong Miao, Jiangtao Wang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Tumor Hypoxia: How Conventional Histology Is Reshaped in Breast Carcinoma.International journal of molecular sciences · 2025
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruochen BaoThyroid and Breast Surgery, Yantai Affiliated Hospital of Binzhou Medical University, The 2ndMedical College of Binzhou Medical University, Yantai, China.
Hongtao QuEmergency Department of Yantai Mountain Hospital, Yantai, China.
Baifeng LiThyroid and Breast Surgery, Yantai Affiliated Hospital of Binzhou Medical University, The 2ndMedical College of Binzhou Medical University, Yantai, China.
Kai ChengThyroid and Breast Surgery, Yantai Affiliated Hospital of Binzhou Medical University, The 2ndMedical College of Binzhou Medical University, Yantai, China.
Yandong MiaoCancer Center, Yantai Affiliated Hospital of Binzhou Medical University, The 2nd Medical College of Binzhou Medical University, Yantai, China.
Jiangtao WangThyroid and Breast Surgery, Yantai Affiliated Hospital of Binzhou Medical University, The 2ndMedical College of Binzhou Medical University, Yantai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) has become a thorny problem in the treatment of breast cancer because of its high invasiveness, metastasis and recurrence. Although immunotherapy has made important progress in TNBC, immune escape caused by many factors, especially metabolic reprogramming, is still the bottleneck of TNBC immunotherapy. Regrettably, the mechanisms responsible for immune escape remain poorly understood. Exploring the mechanism of TNBC immune escape at the metabolic level provides a target and direction for follow-up targeting or immunotherapy. In this review, we focus on the mechanism that TNBC affects immune cells and interstitial cells through hypoxia, glucose metabolism, lipid metabolism and amino acid metabolism, and changes tumor metabolism and tumor microenvironment. This will help to find new targets and strategies for TNBC immunotherapy.

Indexed as

Triple Negative Breast NeoplasmsTumor EscapeTumor MicroenvironmentAnimalsCellular ReprogrammingFemaleHumansImmunotherapyLipid MetabolismMetabolic Reprogrammingamino acid metabolismglucose metabolismhypoxiaimmune escapelipid metabolismtriple-negative breast cancer

Identifiers

PMID39192979
PMCPMC11347331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.